Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose.

Oral treatment with methylprednisolone was as effective as intravenous treatment in acute relapse of MS and no significant difference in response when disability or functional scores were compared in the two groups.

Abstract

A randomised double-blind placebo-controlled trial of intravenous methylprednisolone versus oral methylprednisolone at equivalent high dose was carried out on 35 patients with an acute relapse of multiple sclerosis (MS). After baseline evaluation each was randomly allocated to oral treatment and intravenous placebo or intravenous treatment and oral placebo, receiving 500 mg of methylprednisolone for five consecutive days and with reassessment at days five and twenty-eight. There was no significant difference in response when disability or functional scores were compared in the two groups. Adverse effects were minor and equally distributed. In this study oral treatment with methylprednisolone was as effective as intravenous treatment in acute relapse of MS.